Predictive markers for anti-inflammatory treatment response in thyroid eye disease

Haiyang Zhang; Jingyuan Fan; Jialu Qu; Qinghe Han; Huifang Zhou; Xuefei Song

doi:10.3389/fendo.2023.1292519

Predictive markers for anti-inflammatory treatment response in thyroid eye disease

Front Endocrinol (Lausanne). 2023 Dec 4:14:1292519. doi: 10.3389/fendo.2023.1292519. eCollection 2023.

Authors

Haiyang Zhang^#^{1

2}, Jingyuan Fan^#^{1

2}, Jialu Qu^{1

2}, Qinghe Han³, Huifang Zhou^{1

2}, Xuefei Song^{1

2}

Affiliations

¹ Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
³ Department of Radiology, The Second Hospital of Jilin University, Changchun, Jilin, China.

^# Contributed equally.

Abstract

Anti-inflammatory treatment is the primary and vital therapeutic approach for active, moderate-to-severe thyroid eye disease (TED). Accurate pretreatment prediction of treatment response is of paramount importance for the prognosis of patients. However, relying solely on the clinical activity score asa determinant of activity has led to unsatisfactory treatment outcomes. In recent years, significant advancements have been made in identifying predictive markers for anti-inflammatory treatment response in TED, clinical markers, body fluid biomarkers and imaging biomarkers. Several clinical studies have developed prediction models based on these markers. However, there is still a lack of comprehensive elucidation or comparison between the different markers. Therefore, this review aims to provide a detailed analysis of the definition, characteristics, and application of predictive markers for anti-inflammatory treatment response in TED. Through detailed literature search, 26 articles applying anti-inflammatory treatment effect prediction with a total of 1948 TED patients were used for analysis and discussion. By gaining a better understanding of the current research on predictive markers, we can accelerate and guide the exploration of treatment prediction strategies, leading us towards an era of precise therapy for TED.

Keywords: anti-inflammatory; biomarker; intravenous glucocorticoids; thyroid eye disease; treatment response prediction.

Publication types

Review
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Inflammatory Agents / therapeutic use
Biomarkers
Graves Ophthalmopathy* / diagnosis
Graves Ophthalmopathy* / drug therapy
Humans
Prognosis
Treatment Outcome

Substances

Anti-Inflammatory Agents
Biomarkers

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (81930024, 82271122); the Science and Technology Commission of Shanghai (20DZ22708); Shanghai Key Clinical Specialty, Shanghai Eye Disease Research Center (2022ZZ01003); Clinical Acceleration Program of Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine (JYLJ202202); Jilin Province Natural Science Foundation (20190201218JC).